— ICER to assess apixaban and rivaroxaban, two drugs that seem likely to be among those in the first cycle of drug price negotiation —
— Report will follow structure and restrictions on drug price negotiation elements defined in the Inflation Reduction Act and subsequent CMS guidance —
BOSTON, July 11, 2023 – The Institute for Clinical and Economic Review (ICER) announced today that it is developing a special report evaluating the evidence on apixaban (Eliquis®, Bristol-Myers Squibb) and rivaroxaban (Xarelto®, Bayer) for the treatment of nonvalvular atrial fibrillation (NVAF). ICER plans to release this report in September 2023 and submit it to the Centers for Medicare and Medicaid Services (CMS) as part of the public comment process defined in CMS guidance. The report will be tailored to reflect the legislative specifications in the Inflation Reduction Act and subsequent CMS guidance regarding the information that CMS will use to make initial offers and pursue drug price negotiation on selected drugs.
Eliquis and Xarelto figure prominently among those drugs with high Medicare expenditure that are expected by many to be selected among the first group of drugs for price negotiation beginning later this year.
The Institute for Clinical and Economic Review (ICER) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.